FDA Urges More Switch Sponsor Efforts At Pre-Clinical Stage
This article was originally published in The Tan Sheet
Executive Summary
Firms submitting switch applications should put more focus on pre-clinical testing, according to Dr. Andrea Leonard-Segal, director of the Division of Nonprescription Clinical Evaluation in FDA's Center for Drug Evaluation and Research
You may also be interested in...
ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
FDA's Office of Nonprescription Products may examine issues surrounding actual-use trials for OTC drugs at an advisory committee meeting later this year
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers